Geron Corp (GERN): Cutting PT From $6 To $5 - FBR

September 13, 2016 7:56 AM EDT
Get Alerts GERN Hot Sheet
Price: $1.96 -2.49%

Rating Summary:
    5 Buy, 5 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 50 | New: 20
Trade GERN Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

FBR Capital analyst, Thomas Yip, reiterated his Outperform rating on shares of Geron Corporation (NASDAQ: GERN) but cut his price target to $5 from $6 based on amendments to the Phase II IMbark trial of imetelstat for the treatment of myelofibrosis (MF). The reduced PT is due to a higher clinical risk for imetelstat and a six-month delay of the projected approval for the MF indication (from late 2021 to mid-2022).

Despite the discontinued low dose arm (4.7 mg/kg), the analyst anticipates IMbark to go on with high dose imetelstat (9.4 mg/kg) without delay.

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $2.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment